Abstract
Immune checkpoint inhibitors (ICIs) are a cornerstone in oncological treatment, and are known to induce gastrointestinal side effects, most commonly colitis. However less commonly, immune checkpoint inhibitors can cause gastritis in patients. We present a 71-year-old male with a history of metastatic castrate-resistant prostatic carcinoma on pembrolizumab therapy who presented to the emergency department with melaena, haematemesis and anaemia. Gastroscopy revealed blood in stomach, sloughy and erythematous gastric mucosa, multiple antral erosions and ulcerations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
